Treatment of IgE-mediated disease
US9617325B2 · kind B2 · utility
0Cited by
4References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 29, 2014 |
| Grant date | Apr 11, 2017 |
| Priority date | — |
| Expiry date | Dec 29, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble CD23 (sCD23) that binds and sequesters IgE. Thus, the sCD23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased IgE levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.